Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Alzamend Neuro, Inc. (ALZN)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/29/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Submission of Matters to... |
| 09/26/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/24/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 08/16/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/11/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/10/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 08/07/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and... |
| 08/02/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 07/27/2023 |
10-K
| Annual Report for the period ended April 30, 2023 |
| 05/26/2023 |
4
| AULT MILTON C III (10% Owner) has filed a Form 4 on Alzamend Neuro, Inc.|
Txns:
| Bought 18,000 shares
@ $0.5947, valued at
$10.7k
|
|
| 05/02/2023 |
4
| Jackman Stephan (CEO) has filed a Form 4 on Alzamend Neuro, Inc.|
Txns:
| Bought 37,000 shares
@ $0.5405, valued at
$20k
|
|
| 04/26/2023 |
8-K
| Quarterly results |
| 04/25/2023 |
8-K
| Quarterly results |
| 04/03/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Alzamend Neuro Announces the Initiation of a Phase I/IIA Trial for Its Immunotherapy Vaccine to Treat Mild to Moderate Dementia of the Alzheimer’ s Type ATLANTA, GA, April 3, 2023 -- Alzamend Neuro, Inc. , an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’ s disease , bipolar disorder, major depressive disorder and post-traumatic stress disorder , today announced the initiation of a phase I/IIA clinical trial for its immunotherapy vaccine to treat mild to moderate dementia of the Alzheimer’ s type. The purpose of this trial is to assess the safety, tolerability, and efficacy of multiple ascending doses of ALZN002 compared with that of placebo in 20-30 subjects with mild to moderate morbidity. The primary goal of this clini..." |
|
| 03/31/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/23/2023 |
4
| McGrath Lynne Fahey (Director) has filed a Form 4 on Alzamend Neuro, Inc.|
Txns:
| Bought 10,000 shares
@ $0.435, valued at
$4.4k
|
|
| 03/22/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 03/20/2023 |
4
| AULT MILTON C III (10% Owner) has filed a Form 4 on Alzamend Neuro, Inc.|
Txns:
| Bought 4,000 shares
@ $0.5014, valued at
$2k
Bought 5,000 shares
@ $0.4298, valued at
$2.1k
|
|
| 03/16/2023 |
8-K
| Quarterly results|
Docs:
|
"Alzamend Neuro, Inc. Condensed Balance Sheets January 31, 2023 April 30, 2022 ASSETS CURRENT ASSETS Cash $ 7,375,841 $ 14,063,811 Prepaid expenses and other current assets 546,303 349,723 Prepaid expenses - related party 494,668 - TOTAL CURRENT ASSETS 8,416,812 14,413,534 Property, plant and equipment, net 85,166 102,909 TOTAL ASSETS $ 8,501,978 $ 14,516,443 LIABILITIES AND STOCKHOLDERS’ EQUITY CURRENT LIABILITIES Accounts payable and accrued liabilities $ 2,642,473 $ 1,162,850 Related party payable - 2,082 TOTAL CURRENT LIABILITIES 2,642,473 1,164,932 TOTAL LIABILITIES 2,642,473 1,164,932 COMMITMENTS AND CONTINGENCIES STOCKHOLDERS’ EQUITY Convertible Preferred stock, $0.0001 par value: 10,000,000 shares authorized; Series A Convertible Preferred Stock, $0.0001stated value per share, 1,360..." |
|
| 03/15/2023 |
10-Q
| Quarterly Report for the period ended January 31, 2023 |
| 02/28/2023 |
4
| Horne William B. (Director) has filed a Form 4 on Alzamend Neuro, Inc.|
Txns:
| Exercised 500,000 options to buy
@ $0.004, valued at
$2k
|
|
| 02/03/2023 |
8-K
| Quarterly results |
| 01/20/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 12/29/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/23/2022 |
4
| AULT MILTON C III (10% Owner) has filed a Form 4 on Alzamend Neuro, Inc.|
Txns:
| Bought 5,000 shares
@ $0.8099, valued at
$4k
|
|
| 12/20/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/12/2022 |
10-Q
| Quarterly Report for the period ended October 31, 2022 |
| 11/30/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/30/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/30/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/30/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/21/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/16/2022 |
8-K
| Quarterly results |
| 11/15/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|
|
|